August 10, 2020 10:33 AM EDT

Eli Lilly teams with Pieris on HER2+ tumors; Opdivo + Yervoy best chemo in mesothelioma

Max Gelman

Senior Editor

Jason Mast

Editor

Despite the FDA putting a partial clinical hold on its lead program only a few weeks ago, Boston-based Pieris Pharmaceuticals is plowing forward with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly teams with Pieris on HER2+ tumors; Opdivo + Yervoy best chemo in mesothelioma

Max Gelman

Senior Editor

Jason Mast

Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Eli Lil­ly teams with Pieris on HER2+ tu­mors; Op­di­vo + Yer­voy best chemo in mesothe­lioma

Senior Editor

Editor

Sign up to read this article for free.

Eli Lilly teams with Pieris on HER2+ tumors; Opdivo + Yervoy best chemo in mesothelioma